Typhoid fever continues to be a major public health concern, particularly in many low-and middle-income countries. The current threats of increasing antimicrobial resistance, urbanization, and climate change elevate the urgency for better prevention and control efforts for typhoid fever. In 2017, the results of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization prequalification of a TCV, and global policy and financing decisions have set the stage for the introduction of TCVs into routine immunization programs in endemic countries. Country-level decision-making and program planning are critical for local uptake and sustainability.
1.Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA 2.Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England 3.PATH, Seattle, WA USA
Recommended Citation:
Neuzil, Kathleen M.,Pollard, Andrew J.,Marfin, Anthony A.. Introduction of Typhoid Conjugate Vaccines in Africa and Asia[J]. CLINICAL INFECTIOUS DISEASES,2019-01-01,68:S27-S30